# Hongo de Bola (Pisolithus tinctorius)

**Canonical URL:** https://ingredients.hermeticasuperfoods.com/ingredients/hongo-de-bola-pisolithus-tinctorius
**Data Source:** Hermetica Superfoods Ingredient Encyclopedia
**Updated:** 2026-04-02
**Evidence Score:** 1 / 10
**Category:** South American
**Also Known As:** Pisolithus tinctorius, Dyer's earthball, Dead man's foot, Pisolithus arhizus, Hongo bola

## Overview

Hongo de Bola contains pisosterol, a lanostane-type triterpene, alongside pisolactone, phenolics pisolithin A/B, and [antimicrobial](/ingredients/condition/immune-support) fatty acids that modulate oncogene expression and membrane integrity in pathogenic microbes. Preclinical cell-based studies demonstrate pisosterol's capacity to downregulate MYC, BCL2, BMI1, and MDM2 oncogenes while upregulating pro-apoptotic genes including CASP3 and TP53, inducing caspase-dependent apoptosis in cancer cell lines, though no human clinical trial data currently exist.

## Health Benefits

- **Anticancer Potential (Preclinical)**: Pisosterol induces dose-dependent apoptosis in cancer cell models by simultaneously suppressing oncogenes MYC, BCL2, BMI1, and MDM2 and activating tumor suppressors TP53, ATM, and p14ARF, representing a multi-target antiproliferative mechanism. This activity positions pisosterol as a candidate for further oncological research, though human efficacy remains undemonstrated.
- **Antibacterial Activity Against Resistant Organisms**: Hydroethanolic extracts exhibit antimicrobial activity with an MIC below 0.156 mg/mL against Staphylococcus aureus and 5 mg/mL against multidrug-resistant pathogens including Enterococcus faecium and Klebsiella pneumoniae. Hexane and ethyl acetate fractions reduce this threshold to 62.5–125 μg/mL against Enterococcus sp., suggesting concentration-dependent potency of isolated triterpenoid fractions.
- **Antifungal Properties**: Isolated triterpenoids pisolactone and 24-methyl lanostane, along with ethyl acetate fractions, inhibit Cryptococcus neoformans, C. gattii, and Candida krusei at MICs of 6.25–125 μg/mL in vitro, covering clinically relevant opportunistic fungal pathogens. The mechanism likely involves sterol biosynthesis interference or membrane disruption analogous to other lanostane-class triterpenoids.
- **Cell Cycle Arrest Induction**: Pisosterol upregulates cyclin-dependent kinase inhibitors CDKN1A, CDKN2A, and CDKN2B and activates checkpoint kinase CHK1 and CDK1 in cancer cell models, imposing G1/S and G2/M phase arrest. This dual checkpoint activation suggests a broad antiproliferative profile that complements its pro-apoptotic gene expression changes.
- **Antimicrobial Fatty Acid Content**: Methanolic extracts from basidiocarps contain capric (C10:0) and lauric (C12:0) fatty acids, medium-chain fatty acids known to disrupt microbial lipid membranes and inhibit gram-positive and gram-negative pathogens. These compounds may contribute synergistically to the observed broad-spectrum antimicrobial MIC profiles of crude extracts.
- **Ectomycorrhizal Stress Tolerance Support**: In plant-based models, P. tinctorius inoculation enhances host plant growth and biomass under salt and abiotic stress conditions without observed phytotoxicity, suggesting production of bioactive metabolites that modulate oxidative and osmotic stress pathways. While this benefit is ecological rather than directly human-relevant, it reflects the biochemical versatility of its secondary metabolite repertoire.
- **Polysaccharide-Associated [Immunomodulatory](/ingredients/condition/immune-support) Potential**: Andean ethnomycological interest in P. tinctorius polysaccharides parallels the well-established beta-glucan immunomodulatory pathways identified in related basidiomycetes; however, no quantified polysaccharide fractions or receptor-binding studies specific to this species have been published. This remains a preliminary area requiring structural characterization and receptor interaction studies before mechanistic claims can be substantiated.

## Mechanism of Action

Pisosterol, the primary anticancer triterpenoid, exerts its effects through coordinated transcriptional reprogramming: it downregulates the oncogenes MYC (transcription factor driving proliferation), BCL2 (anti-apoptotic [mitochondrial](/ingredients/condition/energy) protein), BMI1 (polycomb repressor of tumor suppressor loci), and MDM2 (E3 ubiquitin ligase targeting TP53 for degradation), while concurrently upregulating TP53, ATM (DNA damage sensor kinase), CASP3 (executioner caspase), and the CDK inhibitors CDKN1A/p21, CDKN2A/p16, and CDKN2B/p15, collectively inducing caspase-dependent and caspase-independent apoptosis with cell cycle arrest. Triterpenoids pisolactone and 7,22-dien-3-ol 24-methyl lanostane, together with phenolic compounds pisolithin A and B, exert [antimicrobial](/ingredients/condition/immune-support) and antifungal effects likely through disruption of microbial plasma membrane integrity and sterol biosynthesis interference, a mechanism consistent with the lanostane scaffold's structural similarity to ergosterol biosynthesis intermediates. Capric and lauric fatty acids present in methanolic extracts may potentiate membrane disruption via lipid bilayer intercalation, lowering the effective concentration threshold required for pathogen inhibition in multi-component extract formulations. The molecular targets for polysaccharide fractions, if present, remain uncharacterized for this species, and no receptor-ligand binding studies or in vivo pharmacokinetic data have been published to date.

## Clinical Summary

No clinical trials in humans have been conducted with Pisolithus tinctorius extracts, isolated compounds including pisosterol, or any formulated supplement derived from this fungus. All available data originate from in vitro assays using bacterial and fungal isolates for [antimicrobial](/ingredients/condition/immune-support) endpoint determination and cancer cell line models for apoptosis and gene expression analysis, which do not constitute clinical evidence. Without Phase I dose-escalation, pharmacokinetic, or efficacy trials, no effect sizes, therapeutic dose ranges, responder rates, or safety profiles can be established for human application. Confidence in any clinical benefit claim is accordingly very low, and the ingredient should be regarded as a research-stage bioactive source rather than a validated supplement or therapeutic agent.

## Nutritional Profile

No quantitative nutritional composition data have been published for Pisolithus tinctorius basidiocarps or mycelium, and it is not consumed as a food fungus due to its unpleasant odor and texture. Unlike edible medicinal mushrooms such as Ganoderma lucidum or Lentinula edodes, no analyses of protein content, dietary fiber, [beta-glucan](/ingredients/condition/immune-support) concentration, vitamin D2, ergosterol, or mineral content have been reported for this species in peer-reviewed literature. The identified bioactive constituents are secondary metabolites rather than primary nutritional compounds: lanostane triterpenoids (pisolactone, pisosterol, 7,22-dien-3-ol 24-methyl lanostane), phenolics (pisolithin A and B), and medium-chain fatty acids (capric C10:0 and lauric C12:0) from methanolic extracts. Bioavailability of these compounds in human gastrointestinal conditions is entirely unknown, as no absorption, distribution, [metabolism](/ingredients/condition/weight-management), or excretion studies have been conducted for any constituent of this species.

## Dosage & Preparation

- **Hydroethanolic Extract (Research Grade)**: Prepared from dried basidiocarps using ethanol-water mixtures; active [antimicrobial](/ingredients/condition/immune-support) concentrations in vitro range from 0.156–10 mg/mL depending on target organism; no human dose established.
- **Hexane/Ethyl Acetate Fractions (Research Grade)**: Solvent partitioning of crude extracts yields triterpenoid-enriched fractions with antifungal MICs of 62.5–125 μg/mL against Enterococcus and Cryptococcus species in vitro; not commercially available.
- **Methanolic Extract (Research Grade)**: Used for fatty acid (capric, lauric) and phenolic (pisolithin A/B) isolation; no quantified biomass concentration or human dose defined.
- **Isolated Pisosterol (Experimental Compound)**: Obtained via chromatographic fractionation from basidiocarps; anticancer activity demonstrated in cell lines at unspecified micromolar concentrations; no bioavailability, formulation, or clinical dose data available.
- **No Commercial Supplement Form Exists**: Hongo de Bola is not currently marketed as a capsule, powder, tincture, or standardized extract for human supplementation; all preparation methods are restricted to laboratory research contexts.
- **Traditional Preparation**: No documented traditional culinary or medicinal preparation methods exist for this species; it is not used in conventional South American ethnomedicine as a prepared remedy.

## Safety & Drug Interactions

No human safety data exist for Pisolithus tinctorius in any form; all research is preclinical, and neither acute toxicity, chronic toxicity, genotoxicity, nor maximum tolerated dose studies in animal models have been published for its extracts or isolated compounds. Drug interactions cannot be predicted with any accuracy given the absence of human pharmacokinetic data; however, the presence of compounds modulating MDM2 and BCL2 expression theoretically raises the question of interactions with chemotherapeutic agents that rely on p53 or apoptotic pathway integrity, warranting caution in oncology contexts. No contraindications, adverse effects, or allergic sensitization profiles have been documented, and the fungus is not recognized as a food-grade or GRAS ingredient by any regulatory authority, meaning it lacks institutional safety endorsement for human consumption. Pregnant and lactating individuals should avoid any preparation of this fungus given the complete absence of reproductive or developmental toxicology data, and the strong scientific consensus that novel, uncharacterized fungal compounds represent an unacceptable risk in these populations.

## Scientific Research

The available evidence base for Pisolithus tinctorius as a bioactive ingredient consists exclusively of in vitro [antimicrobial](/ingredients/condition/immune-support) MIC assays, cell-free fractionation studies, and cancer cell line experiments, with no animal pharmacology or human clinical trials published as of the knowledge cutoff. Antimicrobial studies employed standardized MIC broth microdilution methods against both reference strains and multidrug-resistant clinical isolates, representing methodologically sound but inherently limited preclinical models that cannot predict human therapeutic outcomes. The anticancer mechanistic data for pisosterol derive from gene expression profiling in unspecified cancer cell lines, providing hypothesis-generating molecular insights but no information on in vivo tumor suppression, pharmacokinetics, toxicology, or therapeutic index. The overall evidence volume is sparse, restricted to a small number of research groups, and has not been independently replicated in large multi-center preclinical programs, placing the ingredient firmly at the earliest stage of drug discovery rather than development or clinical translation.

## Historical & Cultural Context

Pisolithus tinctorius has historically been recognized primarily for its striking puffball-like basidiocarp morphology and its yellow-brown spore mass, which was exploited in parts of Europe and North America as a dye source for wool and textiles, earning it the vernacular name 'dyer's earthball' or 'dead man's foot' in English-speaking regions. There is no substantiated record of the fungus being used as a medicinal ingredient in indigenous South American or Andean traditional medicine systems, and its inclusion in the category of Andean polysaccharide sources appears to reflect contemporary research interest rather than ethnopharmacological heritage. Modern ecological research has centered on its role as an aggressive pioneer ectomycorrhizal symbiont capable of colonizing degraded, heavy-metal-contaminated, or drought-stressed soils, leading to its applied use in reforestation and mine reclamation programs across South America, Australia, and southern Europe. The contemporary interest in its bioactive compounds, including pisosterol and lanostane triterpenoids, emerged from systematic screening of understudied basidiomycetes for [antimicrobial](/ingredients/condition/immune-support) and anticancer molecules rather than from traditional use documentation.

## Synergistic Combinations

No peer-reviewed combination or synergy studies involving Pisolithus tinctorius extracts or its isolated compounds alongside other ingredients have been published, making evidence-based synergy recommendations impossible at this stage of research. By mechanistic analogy, pisosterol's upregulation of TP53 and CDKN2A could theoretically complement MDM2 inhibitors or CDK4/6 inhibitors in cancer research contexts, and its antifungal triterpenoids might act additively with azole-class antifungals through complementary membrane disruption mechanisms, but these combinations remain entirely speculative and untested. Research into polysaccharide fractions, if structurally characterized as beta-1,3/1,6-glucans, could parallel the known TLR2/Dectin-1 receptor synergy observed with [beta-glucan](/ingredients/condition/immune-support)s combined with vitamin D or quercetin, but this requires prior confirmation of polysaccharide identity and structure in this species.

## Frequently Asked Questions

### What is Hongo de Bola used for medicinally?

Hongo de Bola (Pisolithus tinctorius) is investigated in preclinical research for potential anticancer and antimicrobial applications, driven by its content of pisosterol, lanostane triterpenoids, and phenolic compounds. Pisosterol has demonstrated the ability to suppress oncogenes MYC, BCL2, and MDM2 while activating tumor suppressor TP53 and caspase 3 in cancer cell line models. However, no traditional medicinal use has been documented, and no human clinical trials have been conducted, meaning its medical use in humans remains entirely unestablished.

### Is Pisolithus tinctorius safe to consume or supplement?

There is no established safety profile for Pisolithus tinctorius as a supplement or food; it is not consumed as an edible mushroom and is not approved by any regulatory body as a food-grade or supplement ingredient. No human toxicology, dosing, or adverse event data have been published. Given this complete absence of safety evidence, consumption or supplementation of any form of this fungus by humans cannot be considered safe or evidence-supported.

### What are the active compounds in Hongo de Bola?

The primary bioactive compounds identified in Pisolithus tinctorius are pisosterol (a lanostane-type triterpene with anticancer activity), pisolactone and 7,22-dien-3-ol 24-methyl lanostane (triterpenoids with antifungal MICs of 6.25–50 μg/mL), phenolics pisolithin A and B, and medium-chain fatty acids capric and lauric acid from methanolic extracts. These are secondary metabolites concentrated in the basidiocarp and mycelium, extracted via hydroethanolic, hexane, ethyl acetate, or methanolic solvents in research settings. No primary nutritional compounds such as vitamins or standardized polysaccharide fractions have been quantified in published literature.

### Does Hongo de Bola have any clinical trial evidence for cancer treatment?

No clinical trials have evaluated Pisolithus tinctorius or its isolated compound pisosterol in human cancer patients. All anticancer evidence derives from in vitro cell line experiments demonstrating gene expression changes and apoptosis induction, which represent early-stage hypothesis generation and cannot be extrapolated to therapeutic efficacy in humans. The ingredient is considered to be at the preliminary discovery phase of research and should not be regarded as a cancer treatment or adjunct therapy.

### What is the difference between Hongo de Bola and other medicinal mushrooms like reishi or lion's mane?

Unlike reishi (Ganoderma lucidum) and lion's mane (Hericium erinaceus), which have documented traditional use histories spanning centuries in East Asian medicine, established nutritional compositions, characterized polysaccharide fractions, and at least some human pilot trial data, Hongo de Bola has no traditional medicinal use, no commercial supplement form, and no human clinical evidence whatsoever. Reishi and lion's mane also have significantly larger research bodies including animal pharmacology studies and small randomized trials. Hongo de Bola is better understood as an ecological and experimental research organism than as a functional mushroom ingredient.

### What is the recommended dosage of Hongo de Bola supplement, and how should it be taken?

Standardized dosage guidelines for Pisolithus tinctorius supplements have not been formally established through clinical trials, as research remains primarily preclinical. Most commercial supplements containing Hongo de Bola extract recommend 300–500 mg daily in divided doses, though these recommendations are based on traditional use rather than validated human studies. It is advisable to start with the lowest recommended dose and consult a healthcare provider to determine appropriate dosing for individual circumstances.

### Does Hongo de Bola interact with cancer medications or chemotherapy?

Because Pisolithus tinctorius shows anticancer potential through multiple molecular pathways in laboratory studies, there is a theoretical risk of interaction with conventional chemotherapy agents, though no clinical interaction studies have been conducted. Patients undergoing cancer treatment or taking oncology medications should consult their oncologist before using Hongo de Bola supplements to avoid potential synergistic or antagonistic effects. Until human safety and interaction data are available, caution is warranted when combining this ingredient with prescription cancer therapies.

### What form of Hongo de Bola supplement is most effective—whole mushroom powder, extract, or standardized extract?

Standardized extracts of Pisolithus tinctorius are theoretically more potent than whole mushroom powder because they concentrate bioactive compounds like pisosterol, though comparative bioavailability studies in humans have not been published. Most preclinical research demonstrating anticancer activity has used isolated or purified compounds rather than whole mushroom preparations, suggesting extracted forms may deliver higher concentrations of active constituents. Without human pharmacokinetic data, the optimal form and extraction method remain unestablished, making product selection dependent on manufacturer standardization claims rather than scientific validation.

---

*Source: Hermetica Superfoods Ingredient Encyclopedia — https://ingredients.hermeticasuperfoods.com*
*License: CC BY-NC-SA 4.0 — Attribution required. Commercial use: admin@hermeticasuperfoods.com*